Loading asset research
Q3 2026 earnings · Oct 1
Chemomab Therapeutics Ltd. American Depositary Share
CMMBNasdaq · USD · StocksQuote as of · Exchange session not verified$2.16
-1.82%
Today
CMMB
Loading 1D prices…
Market cap
$16M
Volume
63.2K
52w high
$3.5852w low
$1.35Company profile
Chemomab Therapeutics Ltd. American Depositary Share
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
TEL AVIV, United States
Fiscal year end
1231
CIK
1534248
Session & valuation
Open$2.20
Previous close$2.20
Day high$2.26
Day low$2.10
30-day avg. volume111K
Outstanding shares575.4M
Diluted EPS$0.018
Latest annual period
P/E (trailing)120.00
P/E (forward)-72.67
Price / book1.82
Beta0.76
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ACTUActuate Therapeutics Inc. Common stock | $16M | $0.00 | — | -$1.06 | +11.15% | Buy |
| CTXRCitius Pharmaceuticals Inc. Common Stock | $16M | $7.1M | -695.59% | -$1.64 | +1.58% | Hold |
| LSTALisata Therapeutics Inc. Common Stock | $16.1M | $170K | -9756.47% | -$1.91 | +5.33% | Hold |
| LTRNLantern Pharma Inc. Common Stock | $15.6M | $0.00 | — | -$1.57 | +1.03% | Buy |
| KTTAPasithea Therapeutics Corp. Common Stock | $16.5M | $0.00 | — | -$2.91 | -2.92% | Buy |